Browse
related articles
Under the terms of the agreement, Ethypharm will be responsible for the development and supply of the five products, whereas Globalpharma will be responsible for manufacturing, marketing and distribution of the products in the Middle East and Gulf markets.
The products include (Emidol) Paracetamol 500mg FlashtabŪ (Analgesic Antipyretic); (Emicipro) Ciprofloxacin Sustained Release 1000mg (Antibiotic); (Emiphage) Metformin Sustained Release 1000mg (Antidiabetic); (Emicron) Gliclazide Sustained Release 30mg (Antidiabetic); and Pseudoephedrine Sustained Release 120mg & Cetirizine 5 mg in combination (Antiallergic).
"This agreement strengthens our partnership with Ethypharm and further expands our burgeoning product portfolio," said Dr. Maged Amer, General Manager, Globalpharma.
"Globalpharma is focused on bringing quality pharmaceutical products from globally reputed companies to the Middle East market, and the new marketing and distribution contract with Ethypharm is in line with our corporate objectives. We are certain this move will serve to reinforce our market standing."
Ajey Kumar, Chief Executive Officer of Ethypharm India, said, "We are delighted to take our alliance with Globalpharma to the next level. With this deal, Ethypharm has clearly established a leadership position in the drug delivery segment of Middle East and Gulf region."
Posted by Anne-Birte Stensgaard, Senior News Editor
